Larvol Delta - Tessa-Therapeutics-Announces-Updated-Safety-Efcacy-and-Biomarker-Data-from-Phase-2-Trial-of-Autologous-CD30CART-Therapy-TT11-in-Relapsed-or-Refractory-Classical-Hodgkin-Lymphoma

TT11 - Tessa Therap, UNC Lineberger Comprehensive Cancer Center, Baylor Scott & White Research Institute

https://www.globenewswire.com/news-release/2022/12/12/2572312/0/en/Tessa-Therapeutics-Announces-Updated-Safety-Efficacy-and-Biomarker-Data-from-Phase-2-Trial-of-Autologous-CD30-CAR-T-Therapy-TT11-in-Relapsed-or-Refractory-Classical-Hodgkin-Lymphom.html

Dec 12, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next